Stakeholders Awaiting “Interpretive” 340B Orphan Drug Rule

by Admin | July 16, 2014 11:19 am

July 16, 2014—Federal government lawyers affirmed in a court filing late Monday night that the Health Resources and Services Administration intends “to issue a further interpretive rule or guidance” allowing 340B rural and cancer hospitals to purchase orphan drugs at 340B prices when orphan drugs are used for any indication other than treating the rare disease or condition for which the drug received an orphan designation. The rule is expected at any time. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)
Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2014/07/stakeholders-awaiting-interpretive-340b-orphan-drug-rule/

Copyright ©2026 340binformed.org unless otherwise noted.